Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 7, Number 2—April 2001
THEME ISSUE
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections

State of the Art

Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus

Fred C. Tenover*, James W. Biddle*, and Michael V. Lancaster†
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Bright Ideas, Monterey, California, USA

Main Article

Table 1

Examples of vancomycin interpretive criteria used internationally

Interpretive criteria for vancomycin (µg/mL)
Organizationa
Susceptible
Intermediate
Resistant
NCCLS <4 8-16 >32
CA-SFM <4 8-16 >32
BSAC <4 ------ >8

aNCCLS, National Committee for Clinical Laboratory Standards; CA-SFM, Comité de l'Antibiogramme de la Société Française Microbiologie; BSAC, British Society for Antimicrobial Chemotherapy.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO